Opinion
Video
The panel shares their final insights on differentiated thyroid cancer (DTC) before concluding the OncLive program.
Avelumab Maintenance Improves OS and PFS in Advanced Urothelial Carcinoma, Regardless of Diabetes Status
Obe-Cel Elicits High MRD-Negative Response Rates in R/R B-ALL
Axatilimab Displays Durable Responses in cGVHD Irrespective of Number of Prior Lines of Treatment
UGN-102 Induces Clinically Meaningful CR Rates in Low-Grade, Intermediate-Risk NMIBC
2 Commerce Drive
Cranbury, NJ 08512